Posted by Michael Wonder on 18 May 2021
U.S. FDA accepts regulatory submission for sintilimab in combination with pemetrexed and platinum chemotherapy for the first-line treatment of people with non-squamous non-small cell lung cancer
18 May 2021 - Innovent Biologics and Eli Lilly today jointly announced that the U.S. FDA accepted for review a biologics license application for sintilimab injection in combination with pemetrexed and platinum chemotherapy for the first-line treatment of people with non-squamous non-small cell lung cancer.
This is the first U.S. regulatory submission of sintilimab, a PD-1 inhibitor being developed and commercialised under a global collaboration agreement between Innovent and Lilly.
